Psilocybin - Tryp Therapeutics
Alternative Names: PFN™; TRP-8802; TRP-8803; TRP-8804; TRYP-0082Latest Information Update: 02 Feb 2024
At a glance
- Originator TRYP Therapeutics
- Developer TRYP Therapeutics; University of Michigan
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Binge-eating disorder; Fibromyalgia; Irritable bowel syndrome
- Preclinical Cancer; Complex regional pain syndromes; Pain
Most Recent Events
- 17 Jan 2024 Phase-II clinical trials in Irritable bowel syndrome (Treatment-resistant) in USA (PO) (NCT06206265)
- 08 Jan 2024 Tryp Therapeutics receives approval from the Human Research Ethics Committee (HREC) for TRP 8803 in healthy volunteers
- 08 Jan 2024 TRYP Therapeutics completes a phase-II clinical trials in Binge-eating disorders in USA (PO) (NCT05035927)